<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931473</url>
  </required_header>
  <id_info>
    <org_study_id>NewNetsProject</org_study_id>
    <nct_id>NCT03931473</nct_id>
  </id_info>
  <brief_title>Efficacy of Two Dual Active Ingredient Long Lasting Insecticidal Nets for Control of Malaria Transmitted by Pyrethroid Resistant Vectors in Benin</brief_title>
  <acronym>NNP</acronym>
  <official_title>Efficacy of Two Dual Active Ingredient Long Lasting Insecticidal Nets for Control of Malaria Transmitted by Pyrethroid Resistant Vectors in Benin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche Entomologique de Cotonou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNITAID</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Vector Control Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The massive scale-up of Long Lasting Insecticidal Nets (LLIN) has led to a major reduction in
      malaria burden (up to 50%) in many sub-Saharan African countries. This progress is threatened
      by the wide scale selection of insecticide resistant malaria vectors. New types of LLIN
      combining a mixture of two insecticides have been developed to control resistant mosquitoes.

      The efficacy of two bi-treated LLIN are compared to a standard LLIN in a three-arm, single
      blinded, cluster-randomized trial in Cove, Benin. The arms are; 1/ Royal Guard, a net
      combining pyriproxyfen (PPF), which is known to disrupt female reproduction and fertility of
      eggs, and the pyrethroid alpha-cypermethrin, 2/Interceptor G2, LLIN incorporating a mixture
      of two adulticides with different modes of action; chlorfenapyr and a pyrethroid
      (alpha-cypermethrin), and 3/ The control arm: Interceptor, a standard LLIN treated with
      alpha-cypermethrin.

      The primary outcome of the trial will be malaria case incidence in children aged 6 months to
      10 years.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malaria Case Incidence</measure>
    <time_frame>2 years</time_frame>
    <description>Malaria case incidence in children aged 6 months to 10 years measured through bi-monthly/monthly visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malaria Infection prevalence</measure>
    <time_frame>18 months</time_frame>
    <description>Malaria infection prevalence measured in cross-sectional surveys 6 months and 18 months post- distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Entomological Inoculation Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Malaria</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Interceptor G2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorfenapyr/alpha-cypermethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Royal Guard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyriproxyfen/alpha-cypermethrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interceptor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alpha-cypermethrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bed nets</intervention_name>
    <description>Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net</description>
    <arm_group_label>Interceptor</arm_group_label>
    <arm_group_label>Interceptor G2</arm_group_label>
    <arm_group_label>Royal Guard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for cohort:

          -  Children aged 6 months to 9 years

          -  Resident in study villages

          -  Written, informed consent from guardians

        Exclusion Criteria:

          -  Non-residents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jackie Cook, PhD</last_name>
    <phone>02079272180</phone>
    <email>jackie.cook@lshtm.ac.uk</email>
  </overall_contact>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

